Abstracts tagged "anti-TNF therapy"

Abstract Number: 2475 • 2014 ACR/ARHP Annual Meeting
Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
Edward C. Keystone¹, Josef Smolen², Vibeke Strand³, Thomas Kumke⁴, Irina Mountian⁵, Susan Walker⁶ and Robert B. M. Landewé^7,8, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁸Atrium Medical Center, Heerlen, Netherlands
Background/Purpose Use of imputed or observed data, as well as the patient (pt) population evaluated (eg. intention-to-treat [ITT], completer), affects the interpretation of long-term efficacy…
Abstract Number: 1472 • 2014 ACR/ARHP Annual Meeting
Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes
Maria Sole Chimenti, Alberto Bergamini, Eleonora Baffari, Eleonora Ballanti, Alessia Musto, Paola Conigliaro and Roberto Perricone, Rheumatology, allergology and clinical immunology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy
Background/Purpose Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by infiltration of the synovium by inflammatory cells that destroys the cartilage and the…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
Abstract Number: 2472 • 2014 ACR/ARHP Annual Meeting
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée M. van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike^15,16, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of orthopedics, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Department of Rheumatology, Sasebo City General Hospital, Nagasaki, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tohoku University, Tokyo, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰Department of Clinical Research and Development, UCB Pharma, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc, Tokyo, Japan, ¹³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵NTT Sapporo Medical Center, Sapporo, Japan, ¹⁶Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose The efficacy and safety of certolizumab pegol (CZP)+methotrexate (MTX) therapy compared to MTX alone, in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with…
Abstract Number: 1180 • 2014 ACR/ARHP Annual Meeting
Dynamic Magnetic Resonance Imaging in the Assessment of the Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Results from a Phase IIIb Randomized Study
Mikkel Østergaard¹, Mette Bjørndal Axelsen², Lennart T.H. Jacobsson³, Christopher Schaufelberger³, Michael Sejer Hansen⁴, Johannes W.J. Bijlsma⁵, Anna Dudek⁶, Maria Rell-Bakalarska⁷, Fabienne Staelens⁸, Robert Haake⁹, Britt Sundman-Engberg¹⁰ and Henning Bliddal¹¹, ¹Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ²Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Rheumatology, Gentofte Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Medica Pro Familia, Warsaw, Poland, ⁷Rheuma Medicus, Warsaw, Poland, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Stockholm, Sweden, ¹¹The Parker Institute, Department of Rheumatology, Frederiksberg, Denmark
Background/Purpose Magnetic resonance imaging (MRI) can detect early joint inflammation with high sensitivity, without use of radiation. The MARVELOUS study (NCT01235598), using the OMERACT RA…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Proton Rahman¹, Saeed Shaikh², Michael Starr³, William Bensen⁴, Denis Choquette⁵, Wojciech Olszynski⁶, Maqbool Sheriff⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Susan Otawa¹⁰, Francois Nantel¹¹, Vincent Letourneau¹¹ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²McMaster University, Hamilton, ON, Canada, ³Montreal General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸Université de Montréal, Montreal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…
Abstract Number: 519 • 2014 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study
Boulos Haraoui¹, Gustavo Casado², Elke Theander³, Laszlo Czirják⁴, Andrew Taylor⁵, Peter Button⁶, Lykke Hinsch Gylvin⁷ and Roberto Caporali⁸, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Hospital Militar Central, Buenos Aires, Argentina, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴University of Pécs, Pécs, Hungary, ⁵Royal Perth Hospital, Perth, Australia, ⁶Roche Products Pty Limited, Dee Why, Australia, ⁷F. Hoffmann-La Roche, Basel, Switzerland, ⁸Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in…
Abstract Number: 2343 • 2014 ACR/ARHP Annual Meeting
Therapeutic Effects of Mesenchymal Stem Cells, Anti-Tumor Necrosis Factor and Anti-CD20 Treatment on Collagen Induced Arthritis
Yue Sun¹, Xuebing Feng² and Lingyun Sun², ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). In this study, the effects of mesenchymal stem cells…
Abstract Number: 934 • 2014 ACR/ARHP Annual Meeting
Amelioration of Inflammatory Arthritis By Anti-TNF Therapy Is Associated with Restoration of Lymphatic Contraction
Echoe M. Bouta¹, Igor Kuzin², Karen de Mesy-Bentley¹, Ronald Wood³, Homaira Rahimi⁴, Rui-Cheng Ji⁵, Christopher T. Ritchlin⁶, Andrea Bottaro², Lianping Xing⁷ and Edward M. Schwarz⁸, ¹University of Rochester, Rochester, NY, ²Cooper Medical School, Camden, NJ, ³Department of Urology, University of Rochester Medical Center, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hospit, Rochester, NY, ⁵Department of Anatomy, Biology and Medicine, Oita University, Oita, Japan, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁸Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with episodic flares. In tumor necrosis factor transgenic (TNF-Tg) mice, a model of inflammatory-erosive arthritis,…
Abstract Number: 479 • 2014 ACR/ARHP Annual Meeting
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Rene Westhovens¹, Edward C. Keystone², Clifton O. Bingham III³, Elizabeth C. Hsia^4,5, Lilianne Kim⁴, Yiying Zhou⁴, Alan M. Mendelsohn⁶ and Michael E. Weinblatt⁷, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years Background/Purpose: To describe the safety profile…
Abstract Number: 2203 • 2014 ACR/ARHP Annual Meeting
Adalimumab Therapy Improves Insulin Sensitivity in Non-Diabetic Psoriatic Patients: A 6-Month Prospective Study
Trinitario Pina Murcia¹, Raquel López-Mejías¹, Fernanda Genre¹, Begoña Ubilla¹, Susana Armesto², Marcos A. González-López², María del Carmen Gonzalez-Vela³, Javier Llorca⁴, Ricardo Blanco⁵ and MA González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Dept. of Pathology, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁵Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: psoriasis is a systemic inflammatory condition that shares similarities with other inflammatory immune disorders. In this context, patients with psoriasis are at an increased…
Abstract Number: 932 • 2014 ACR/ARHP Annual Meeting
MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Janneke Anink¹, Marieke H. Otten¹, Lisette W.A. van Suijlekom-Smit¹, Marion A.J. Van Rossum², Koert M. Dolman³, Esther P.A. Hoppenreijs⁴, Rebecca ten Cate⁵, Simona Ursu⁶, Lucy R Wedderburn⁷, Gerd Horneff⁸, Thomas Vogl^9,10, Dirk Föll^10,11, Johannes Roth^9,12 and Dirk Holzinger^10,13, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ³Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, ⁴Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁷Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁹Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁰Interdisciplinary Centre for Clinical Research IZKF, University Hospital Muenster, Muenster, Germany, ¹¹Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ¹²University Hospital Muenster, Muenster, Germany, ¹³Pediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany
Background/Purpose: Biological therapy has dramatically improved the treatment of patients with JIA. However, there is still a group of patients that shows a lack of…
Abstract Number: 467 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort
Lucia Silva-Fernandez^1,2, Mark Lunt¹, Kath D. Watson¹, . BSRBR Control Centre Consortium¹, Deborah P. Symmons¹, Kimme Hyrich¹ and . On behalf of the BSRBR³, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Rheumatology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³British Society for Rheumatology, London, United Kingdom
Background/Purpose: Serious infections (SI) are a major concern in patients treated with tumour necrosis factor inhibitors (TNFi). The RABBIT Risk Score (RRS) (1) allows a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].